Von Willebrand factor antigen: A novel on-treatment predictor of response to antiviral therapy in chronic hepatitis C genotypes 1 and 4

Antiviral Therapy

Volumn 15, Issue 6, 2010, Pages 831-839

  Pramhas, Sibylle ^a   Homoncik, Monika ^a   Ferenci, Peter ^a   Ferlitsch, Arnulf ^a   Scherzer, Thomas ^a   Gangl, Alfred ^a   Peck Radosavljevic, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIGEN; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 8; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA; VON WILLEBRAND FACTOR ANTIGEN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECURRENCE; RIBAVIRIN; VON WILLEBRAND FACTOR;

EID: 77957335230     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1654     Document Type: Article

References (25)

1. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
2. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
3. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006; 355:2444-2451.
4. Lee SS, Ferenci P. Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4. Antivir Ther 2008; 13 Suppl 1:9-16.
5. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43:425-433.
6. Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38:645-652.
7. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147-1171.
8. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357:2482-2494.
9. Mannucci PM. Treatment of von Willebrand's Disease. N Engl J Med 2004; 351:683-694.
10. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350:1387-1397.
11. Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost 2006; 4:1186-1193.
12. Bernardo A, Ball C, Nolasco L, Moake JF, Dong J-F. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 2004; 104:100-106.
13. Lenting PJ, van Schooten CJM, Denis CV. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost 2007; 5:1353-1360.
14. Sieghart W, Homoncik M, Jilma B, et al. Antiviral therapy decreases GpIIb/IIIa activation of platelets in patients with chronic hepatitis C. Thromb Haemost 2006; 95:260-266.
15. Homoncik M, Ferlitsch A, Ferenci P, et al. Short- and longterm effects of therapy with interferon-alpha and pegylated interferon-alpha/ribavirin on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis C. Aliment Pharmacol Ther 2005; 21:49-55.
16. Sul HR, Chung SJ, Lee YJ, et al. Higher response rate from peginterferon alpha 2a plus ribavirin in chronic hepatitis C patients with hemophilia. 59th Annual Meeting of the American Association for the Study of Liver Diseases. 31 October-4 November 2008, San Francisco, CA, USA. Abstract 1256.
17. Ferenci P, Formann E, Laferl H, et al. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naive patients with chronic hepatitis C genotype 1 infection. J Hepatol 2006; 44:275-282.
18. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135:451-458.
19. Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol 2007; 47:598-607.
20. Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47:1884-1893.
21. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004; 140:370-381.
22. Berg T, Sarrazin C, Herrmann E, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003; 37:600-609.
23. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43:954-960.
24. Honda T, Toyoda H, Hayashi K, et al. Ribavirin and use of clotting factors in patients with hemophilia and chronic hepatitis C. JAMA 2005; 293:1190-1192.
25. Chevaliez S, Pawlotsky J-M. Interferon-based therapy of hepatitis C. Adv Drug Deliv Rev 2007; 59:1222-1241.